SLE Patients With Lupus Nephritis Have Higher Cardiovascular Event Risk
Lupus nephritis a risk factor for some, but not all, cardiovascular outcomes in study of patients with SLE.
Lupus Nephritis
Targeted IL-6 Inhibition With Sirukumab Ineffective in Lupus Nephritis
Targeted IL-6 inhibition with sirukumab did not demonstrate efficacy or acceptable safety in patients with active lupus nephritis concomitantly receiving immunosupprsant therapy.
SLE Pregnancy Outcomes Impacted by Maternal Race, Ethnicity
Researchers found significant disparities in pregnancy complications rates and hospitalization costs among white, black, and Hispanic women with systemic lupus erythematosus
Improving Sensitivity of LN Urinary Markers by Combining Panels
Panels of urinary biomarkers were shown to be have increased diagnostic power in predicting complete clinical responses when compared with individual biomarkers.
SLE Renal Outcomes With Mixed LN and Pure Proliferative LN Compared
The association between mixed proliferative lupus nephritis (MPLN), pure proliferative lupus nephritis (PPLN), and short-term renal outcomes was examined in new research.
Anti-Smith Antibodies Indicative of Poor Prognosis in Biopsy-Proven LN
The predictive value for future need for immunosuppression of anti-smith antibodies found on biopsy-proven lupus nephritis was evaluated in a retrospective analysis
Prognostic Significance of Renal Crescents in Lupus Nephritis
In lupus nephritis, a higher proportion of crescents found on kidney biopsy increased the risk for unfavorable outcomes.
Allograft Survival After Renal Transplantation for Lupus Nephritis
Transplantation is a suitable option for some patients with end-stage renal disease associated with lupus nephritis after careful consideration of several factors.
Renal Biopsy: Impact on Diagnosis, Prognosis, and Clinical Decision Making in Lupus Nephritis
Although renal biopsy is relatively safe and serious complications are uncommon, the risk of bleeding and other adverse events remains a key concern.
IL-6, IL-17 Accurate Biomarkers for Systemic Lupus Erythematosus Disease Activity
Systemic lupus erythematosus disease activity can be assessed using IL-6 and IL-17 baseline serum levels as biomarkers.
Next post in General Rheumatology
